{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:14:28Z","timestamp":1762866868620,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.revmed.2016.02.003","type":"journal-article","created":{"date-parts":[[2016,5,26]],"date-time":"2016-05-26T15:50:48Z","timestamp":1464277848000},"page":"674-679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Physiopathologie, d\u00e9marche diagnostique et avanc\u00e9es th\u00e9rapeutiques dans les glom\u00e9rulon\u00e9phrites extra-membraneuses"],"prefix":"10.1016","volume":"37","author":[{"given":"K.","family":"Dahan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2016.02.003_bib0005","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/ndt\/gfp355","article-title":"An overview on frequency of renal biopsy diagnosis in Brazil: clinical and pathological patterns based on 9617 native kidney biopsies","volume":"25","author":"Polito","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.revmed.2016.02.003_bib0010","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2215\/CJN.00710805","article-title":"Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30-year renal biopsy study","volume":"1","author":"Swaminathan","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2016.02.003_bib0015","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3181\/00379727-100-24736","article-title":"Production of nephrotic syndrome in rats by Freund's adjuvants and rat kidney suspension","volume":"100","author":"Heymann","year":"1959","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.revmed.2016.02.003_bib0020","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1084\/jem.157.2.667","article-title":"Immunocytochemical localization of the Heymann nephritis antigen (gp330) in glomerular epithelial cells of normal Lewis rats","volume":"157","author":"Kerjaschki","year":"1983","journal-title":"J Exp Med"},{"key":"10.1016\/j.revmed.2016.02.003_bib0025","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMoa012895","article-title":"Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies","volume":"346","author":"Debiec","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2016.02.003_bib0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic MN","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2016.02.003_bib0035","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2016.02.003_bib0040","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1056\/NEJMoa1013792","article-title":"Early-childhood membranous nephropathy due to cationic bovine serum albumin","volume":"364","author":"Debiec","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2016.02.003_bib0045","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/ki.2012.209","article-title":"Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy","volume":"82","author":"Hoxha","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.revmed.2016.02.003_bib0050","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1681\/ASN.2010090967","article-title":"Anti-phospholipase A2 receptor antibody in membranous nephropathy","volume":"22","author":"Qin","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2016.02.003_bib0055","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/ndt\/gfs439","article-title":"Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy","volume":"28","author":"Svobodova","year":"2013","journal-title":"Nephrol Dial Tranplant"},{"key":"10.1016\/j.revmed.2016.02.003_bib0060","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1681\/ASN.2012070730","article-title":"Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy","volume":"24","author":"Coenen","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2016.02.003_bib0065","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/ki.1988.56","article-title":"Idiopathic membranous nephropathy: the natural history of untreated patients","volume":"33","author":"Donadio","year":"1988","journal-title":"Kidney Int"},{"key":"10.1016\/j.revmed.2016.02.003_bib0070","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJM199307083290203","article-title":"Prognosis of untreated patients with idiopathic membranous nephropathy","volume":"329","author":"Schieppati","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2016.02.003_bib0075","first-page":"73","article-title":"Long-term outcome of idiopathic membranous nephropathy with nephrotic syndrome","volume":"2","author":"Zucchelli","year":"1987","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.revmed.2016.02.003_bib0080","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/ki.2013.476","article-title":"Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy","volume":"85","author":"Lee","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.revmed.2016.02.003_bib0085","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1038\/sj.ki.5001790","article-title":"Membranous nephropathy and cancer: epidemiologic evidence and determinants of high-risk cancer association","volume":"70","author":"Lefaucheur","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.revmed.2016.02.003_bib0090","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1093\/ndt\/gfn363","article-title":"Monoclonal immunoglobulin deposition disease associated with membranous features","volume":"23","author":"Komatsuda","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.revmed.2016.02.003_bib0095","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrneph.2012.35","article-title":"Pathogenesis of membranous nephropathy: recent advances and future challenges","volume":"8","author":"Ronco","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.revmed.2016.02.003_bib0100","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1681\/ASN.2005010028","article-title":"Management of membranous nephropathy: when and what for treatment","volume":"16","author":"Cattran","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2016.02.003_bib0105","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/ki.1997.127","article-title":"Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications","volume":"51","author":"Cattran","year":"1997","journal-title":"Kidney Int"},{"key":"10.1016\/j.revmed.2016.02.003_bib0110","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0272-6386(04)00868-6","article-title":"The treatment of idiopathic membranous nephropathy: a dilemma or a conundrum?","volume":"44","author":"Glassock","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.revmed.2016.02.003_bib0115","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1056\/NEJM198901263200403","article-title":"A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy","volume":"320","author":"Cattran","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2016.02.003_bib0120","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1056\/NEJM198901053200102","article-title":"A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy","volume":"320","author":"Ponticelli","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2016.02.003_bib0125","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/ki.1995.453","article-title":"A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy","volume":"48","author":"Ponticelli","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.revmed.2016.02.003_bib0130","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1681\/ASN.2007020166","article-title":"A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy","volume":"18","author":"Jha","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2016.02.003_bib0135","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/ki.1995.161","article-title":"A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group","volume":"47","author":"Cattran","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.revmed.2016.02.003_bib0140","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/sj.ki.5002215","article-title":"Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial","volume":"71","author":"Praga","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.revmed.2016.02.003_bib0145","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1053\/j.ajkd.2008.04.013","article-title":"Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial","volume":"52","author":"Dussol","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.revmed.2016.02.003_bib0150","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2016.02.003_bib0155","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2215\/CJN.01180307","article-title":"Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy","volume":"2","author":"Cravedi","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2016.02.003_bib0160","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2016.02.003_bib0165","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.ki.5002628","article-title":"Rituximab treatment of idiopathic membranous nephropathy","volume":"73","author":"Fervenza","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.revmed.2016.02.003_bib0170","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J Am Soc Nephrol"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866316000710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866316000710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:37:02Z","timestamp":1759336622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866316000710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0248866316000710"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2016.02.003","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physiopathologie, d\u00e9marche diagnostique et avanc\u00e9es th\u00e9rapeutiques dans les glom\u00e9rulon\u00e9phrites extra-membraneuses","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2016.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI).","name":"copyright","label":"Copyright"}]}}